In this review, we comprehensively summarize the literature published thus far, providing supportive evidence to highlight the prognostic significance of serum ALB level and various ALB-based mono- and combination biomarkers in the prediction of the outcomes of HCC patients receiving different treatment modalities including surgical, locoregional, and systemic therapies. This evidence concerns the gene ALB and hepatocellular carcinoma.